Koji Arihiro
Koji Arihiro publishes mostly in Oncology, Surgery and Pulmonary and Respiratory Medicine, on topics such as Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment and Breast Cancer Treatment Studies.
- World rank
- #709,661 of 7,710,434 ranked researchers
- Rank in Japan
- #8,342 of 383,136
- Works
- 595
- Citations
- 27k
- Citations per work
- 45.0
What does Koji Arihiro research?
Koji Arihiro's work is mostly in Medicine (45%), Biochemistry, Genetics and Molecular Biology (14%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences27045.4%
- Medicine27045.4%
- Everything else24040.4%
- Life Sciences8414.2%
- 1Oncology14% of their works
- 2Surgery14% of their works
- 3Pulmonary and Respiratory Medicine12% of their works
- 4Molecular Biology8% of their works
- 5Cancer Research6% of their works
- 6Epidemiology6% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Breast Cancer Treatment Studies
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
Which keywords describe Koji Arihiro's research?
The keywords of their largest research topics: Neoadjuvant Therapy, Endoscopic Resection, Clinical Practice Guidelines, Survival Analysis, Chemotherapy, Epidemiology, Prognostic Factors and Surgical Management.
- Mutational Signatures
- Cancer Genomics
- Biliary Tract Cancer
- Pancreatic Cancer
- Imatinib Mesylate
- Breast Tumours
- Esophageal Carcinoma
- Gastric Cancer
- Surgical Management
- Epidemiology
- Survival Analysis
- Endoscopic Resection
- Neoadjuvant Therapy
- Clinical Practice Guidelines
- Chemotherapy
- Prognostic Factors
- Tumor Microenvironment
- Molecular Characterization
- Preoperative Chemoradiotherapy
- Gene Expression
- Sunitinib
- Surgical Complications
- Cholangiocarcinoma
- Immune Checkpoint Blockade
- PD-1 and PD-L1
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 25 words, with their numbers
- Neoadjuvant Therapy1133 topics
- Endoscopic Resection1032 topics
- Clinical Practice Guidelines1022 topics
- Survival Analysis1022 topics
- Chemotherapy1002 topics
- Epidemiology722 topics
- Prognostic Factors702 topics
- Surgical Management702 topics
- Tumor Microenvironment682 topics
- Gastric Cancer641 topic
- Molecular Characterization641 topic
- Esophageal Carcinoma391 topic
- Preoperative Chemoradiotherapy391 topic
- Breast Tumours381 topic
- Gene Expression381 topic
- Imatinib Mesylate371 topic
- Sunitinib371 topic
- Pancreatic Cancer361 topic
- Surgical Complications361 topic
- Biliary Tract Cancer331 topic
- Cholangiocarcinoma331 topic
- Cancer Genomics321 topic
- Immune Checkpoint Blockade321 topic
- Mutational Signatures321 topic
- PD-1 and PD-L1321 topic
Where does Koji Arihiro work?
Koji Arihiro's main affiliation in the publication record is Hiroshima University, Japan.
How many publications and citations does Koji Arihiro have?
OpenAlex counts 595 works and 26,764 citations for Koji Arihiro, an h-index of 65, ranking #709,661 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Koji Arihiro. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.